Stryker Co. (NYSE:SYK) Stock Holdings Boosted by Metis Global Partners LLC

Metis Global Partners LLC increased its position in shares of Stryker Co. (NYSE:SYK) by 4.7% during the third quarter, Holdings Channel.com reports. The fund owned 15,280 shares of the medical technology company’s stock after acquiring an additional 692 shares during the quarter. Metis Global Partners LLC’s holdings in Stryker were worth $5,520,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Snider Financial Group lifted its stake in Stryker by 0.4% in the 3rd quarter. Snider Financial Group now owns 11,707 shares of the medical technology company’s stock worth $4,229,000 after acquiring an additional 51 shares in the last quarter. Zions Bancorporation N.A. grew its position in Stryker by 17.1% during the third quarter. Zions Bancorporation N.A. now owns 13,619 shares of the medical technology company’s stock valued at $4,920,000 after purchasing an additional 1,984 shares in the last quarter. KBC Group NV increased its stake in Stryker by 34.1% in the 3rd quarter. KBC Group NV now owns 446,338 shares of the medical technology company’s stock valued at $161,244,000 after buying an additional 113,422 shares during the period. Huntington National Bank boosted its stake in shares of Stryker by 7.6% during the 3rd quarter. Huntington National Bank now owns 267,803 shares of the medical technology company’s stock valued at $96,747,000 after buying an additional 18,936 shares during the period. Finally, Cable Hill Partners LLC increased its stake in shares of Stryker by 45.5% in the third quarter. Cable Hill Partners LLC now owns 1,314 shares of the medical technology company’s stock worth $476,000 after acquiring an additional 411 shares during the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insider Transactions at Stryker

In other Stryker news, CEO Kevin Lobo sold 57,313 shares of the stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the transaction, the chief executive officer now owns 100,027 shares in the company, valued at $36,879,954.90. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Stryker news, CEO Kevin Lobo sold 57,313 shares of the stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $368.70, for a total value of $21,131,303.10. Following the completion of the transaction, the chief executive officer now directly owns 100,027 shares in the company, valued at approximately $36,879,954.90. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Viju Menon sold 600 shares of Stryker stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $355.00, for a total transaction of $213,000.00. Following the sale, the insider now owns 9,069 shares in the company, valued at approximately $3,219,495. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 67,381 shares of company stock worth $24,825,275. 5.90% of the stock is owned by insiders.

Stryker Trading Up 0.4 %

Stryker stock opened at $389.75 on Thursday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.91 and a quick ratio of 1.22. The firm has a 50-day moving average of $362.94 and a 200-day moving average of $346.72. The company has a market cap of $148.58 billion, a price-to-earnings ratio of 41.62, a P/E/G ratio of 2.92 and a beta of 0.91. Stryker Co. has a one year low of $282.35 and a one year high of $390.59.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share for the quarter, topping analysts’ consensus estimates of $2.77 by $0.10. Stryker had a return on equity of 23.07% and a net margin of 16.34%. The firm had revenue of $5.49 billion for the quarter, compared to the consensus estimate of $5.37 billion. During the same quarter in the previous year, the business earned $2.46 earnings per share. The business’s revenue was up 11.9% compared to the same quarter last year. On average, equities analysts expect that Stryker Co. will post 12.06 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the company. StockNews.com raised Stryker from a “hold” rating to a “buy” rating in a research report on Thursday. Royal Bank of Canada lifted their price target on Stryker from $386.00 to $400.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 30th. Robert W. Baird increased their price objective on Stryker from $378.00 to $405.00 and gave the company an “outperform” rating in a research report on Wednesday, October 30th. Needham & Company LLC boosted their target price on shares of Stryker from $393.00 to $409.00 and gave the stock a “buy” rating in a research report on Wednesday, October 30th. Finally, UBS Group increased their target price on shares of Stryker from $366.00 to $370.00 and gave the company a “neutral” rating in a research note on Wednesday, October 30th. Four equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $393.65.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.